Telomir Pharmaceuticals, Common Stock Analysis

TELO Stock   4.02  0.10  2.43%   
Telomir Pharmaceuticals, Common is overvalued with Real Value of 3.43 and Hype Value of 4.0. The main objective of Telomir Pharmaceuticals, stock analysis is to determine its intrinsic value, which is an estimate of what Telomir Pharmaceuticals, Common is worth, separate from its market price. There are two main types of Telomir Pharmaceuticals,'s stock analysis: fundamental analysis and technical analysis.
The Telomir Pharmaceuticals, stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Telomir Pharmaceuticals, is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Telomir Stock trading window is adjusted to America/New York timezone.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telomir Pharmaceuticals, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Telomir Stock Analysis Notes

About 34.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.56. Telomir Pharmaceuticals, had not issued any dividends in recent years. To find out more about Telomir Pharmaceuticals, Common contact Erez Aminov at 786 396 6723 or learn more at https://telomirpharma.com.

Telomir Pharmaceuticals, Investment Alerts

Telomir Pharmaceuticals, generated a negative expected return over the last 90 days
Telomir Pharmaceuticals, has high historical volatility and very poor performance
Net Loss for the year was (16.53 M) with profit before overhead, payroll, taxes, and interest of 0.
Telomir Pharmaceuticals, generates negative cash flow from operations
Telomir Pharmaceuticals, has a poor financial position based on the latest SEC disclosures
About 34.0% of the company outstanding shares are owned by corporate insiders
Latest headline from finance.yahoo.com: Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells

Telomir Largest EPS Surprises

Earnings surprises can significantly impact Telomir Pharmaceuticals,'s stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2025-02-26
2024-12-31-0.05-0.1-0.05100 
View All Earnings Estimates

Telomir Pharmaceuticals, Environmental, Social, and Governance (ESG) Scores

Telomir Pharmaceuticals,'s ESG score is a quantitative measure that evaluates Telomir Pharmaceuticals,'s performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Telomir Pharmaceuticals,'s operations that may have significant financial implications and affect Telomir Pharmaceuticals,'s stock price as well as guide investors towards more socially responsible investments.

Telomir Pharmaceuticals, Thematic Classifications

In addition to having Telomir Pharmaceuticals, stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Health Management Idea
Health Management
Healthcare providers, hospitals
IT Idea
IT
Information technology and IT services
Computers Idea
Computers
USA Equities from Computers industry as classified by Fama & French
Biotech Idea
Biotech
Biotechnology and pharmaceuticals production and services

Telomir Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 117.56 M.

Telomir Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(12.49)(13.11)
Return On Capital Employed(1.32)(1.25)
Return On Assets(12.49)(13.11)
Return On Equity(25.71)(24.42)

Management Efficiency

Telomir Pharmaceuticals, has return on total asset (ROA) of (2.5096) % which means that it has lost $2.5096 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.1018) %, meaning that it created substantial loss on money invested by shareholders. Telomir Pharmaceuticals,'s management efficiency ratios could be used to measure how well Telomir Pharmaceuticals, manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of March 2025, Return On Tangible Assets is likely to drop to -13.11. In addition to that, Return On Capital Employed is likely to grow to -1.25. At this time, Telomir Pharmaceuticals,'s Total Assets are very stable compared to the past year. As of the 29th of March 2025, Total Current Assets is likely to grow to about 1.6 M, while Non Current Assets Total are likely to drop 0.00.
Last ReportedProjected for Next Year
Book Value Per Share 0.02  0.02 
Tangible Book Value Per Share 0.02  0.02 
Enterprise Value Over EBITDA(16.33)(17.15)
Price Book Value Ratio 189.26  198.72 
Enterprise Value Multiple(16.33)(17.15)
Price Fair Value 189.26  198.72 
Enterprise Value108.4 M96.3 M
The decision-making processes within Telomir Pharmaceuticals, are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Return On Assets
(2.51)
Return On Equity
(8.10)

Technical Drivers

As of the 29th of March, Telomir Pharmaceuticals, has the Coefficient Of Variation of (51,887), risk adjusted performance of 0.0069, and Variance of 35.15. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Telomir Pharmaceuticals,, as well as the relationship between them.

Telomir Pharmaceuticals, Price Movement Analysis

Execute Study
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Telomir Pharmaceuticals, middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Telomir Pharmaceuticals,. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Telomir Pharmaceuticals, Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Telomir Pharmaceuticals, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Telomir Pharmaceuticals,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Telomir Pharmaceuticals, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Telomir Pharmaceuticals, Predictive Daily Indicators

Telomir Pharmaceuticals, intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Telomir Pharmaceuticals, stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Telomir Pharmaceuticals, Corporate Filings

8K
19th of March 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
25th of February 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
20th of February 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
18th of February 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
14th of February 2025
Other Reports
ViewVerify
F5
4th of February 2025
The annual filing required by the Securities and Exchange Commission (SEC) from company insiders or beneficial owners
ViewVerify
8K
28th of January 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
7th of January 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify

Telomir Pharmaceuticals, Forecast Models

Telomir Pharmaceuticals,'s time-series forecasting models are one of many Telomir Pharmaceuticals,'s stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Telomir Pharmaceuticals,'s historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Telomir Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Telomir Pharmaceuticals, prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Telomir shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Telomir Pharmaceuticals,. By using and applying Telomir Stock analysis, traders can create a robust methodology for identifying Telomir entry and exit points for their positions.
Last ReportedProjected for Next Year

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Telomir Pharmaceuticals, to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Piotroski F Score Now

   

Piotroski F Score

Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
All  Next Launch Module
When determining whether Telomir Pharmaceuticals, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Telomir Pharmaceuticals,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Telomir Pharmaceuticals, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Telomir Pharmaceuticals, Common Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telomir Pharmaceuticals, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Telomir Pharmaceuticals,. If investors know Telomir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Telomir Pharmaceuticals, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.56)
Return On Assets
(2.51)
Return On Equity
(8.10)
The market value of Telomir Pharmaceuticals, is measured differently than its book value, which is the value of Telomir that is recorded on the company's balance sheet. Investors also form their own opinion of Telomir Pharmaceuticals,'s value that differs from its market value or its book value, called intrinsic value, which is Telomir Pharmaceuticals,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Telomir Pharmaceuticals,'s market value can be influenced by many factors that don't directly affect Telomir Pharmaceuticals,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Telomir Pharmaceuticals,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Telomir Pharmaceuticals, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Telomir Pharmaceuticals,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.